We know, like I said, Secretary Kenney is looking to open the regulatory pathway for stem cells.

And again, the historic FDA stance on not even this new administration. This new administration has made it clear their plan is to open up the regulatory pathways on peptides and stem cells and cash pay products and to figure out a pathway that makes sense for the American people while still honoring the safety and integrity of what they're trying to implement on a grander scale.

In his Senate testimony, he explains that the repeal of Glass-Steagall was a big deal, but on the ground level, what was worse was how the Clinton administration, quote, implemented the Reinventing Government Initiative, which was hostile to regulation and enforcement. We were instructed, pursuant to that initiative, to refer to and think of the industry as our clients.